List of Excipients in Branded Drug NITROFURANTOIN MONOHYDRATE MACROCRYSTALLINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Direct_Rx	NITROFURANTOIN MONOHYDRATE MACROCRYSTALLINE	nitrofurantoin monohydrate	61919-021	CARBOMER 934
Direct_Rx	NITROFURANTOIN MONOHYDRATE MACROCRYSTALLINE	nitrofurantoin monohydrate	61919-021	CARBOMER HOMOPOLYMER TYPE B
Direct_Rx	NITROFURANTOIN MONOHYDRATE MACROCRYSTALLINE	nitrofurantoin monohydrate	61919-021	D&C YELLOW NO. 10
Direct_Rx	NITROFURANTOIN MONOHYDRATE MACROCRYSTALLINE	nitrofurantoin monohydrate	61919-021	FD&C BLUE NO. 1

Excipient Strategy and Commercial Opportunities for Nitrofurantoin Monohydrate/Macrocrystalline

Last updated: August 19, 2026

Nitrofurantoin monohydrate/macrocrystalline is a mature immediate-release urinary antibacterial marketed primarily as 100 mg capsules under Macrobid and generic equivalents. The strongest commercial opportunities are not based on new chemical-entity exclusivity. They are based on reliable bioequivalence, controlled particle-size distribution, excipient supply security, capsule differentiation, and cost-efficient manufacturing.

The product has limited traditional patent leverage. Competitive advantage depends on regulatory execution, manufacturing consistency, pharmacy supply, and differentiated delivery options that preserve the established pharmacokinetic profile.

What is nitrofurantoin monohydrate/macrocrystalline?

Nitrofurantoin monohydrate/macrocrystalline combines two physical forms of nitrofurantoin:

Attribute	Product profile
Active ingredient	Nitrofurantoin monohydrate/macrocrystals
Therapeutic class	Urinary antibacterial
Main indication	Acute uncomplicated cystitis caused by susceptible organisms
Common strength	100 mg capsule
Reference product	Macrobid
FDA regulatory route	NDA for the reference product; ANDA for generics
Dosage form	Oral capsule
Administration	Twice daily with food, according to the prescribing information
Primary market	Outpatient treatment of uncomplicated urinary tract infection

Macrobid uses a 1:1 mixture of nitrofurantoin monohydrate and nitrofurantoin macrocrystals. The formulation is designed to reduce gastrointestinal exposure and permit twice-daily dosing compared with older nitrofurantoin products.[1]

Nitrofurantoin monohydrate/macrocrystalline should be distinguished from:

• Nitrofurantoin macrocrystals, marketed historically as Macrodantin capsules.
• Nitrofurantoin oral suspension, marketed as Furadantin.
• Other nitrofurantoin products that do not use the same active-material ratio or release design.

The distinction matters because a formulation that is pharmaceutically equivalent to one nitrofurantoin product may not be substitutable for every other nitrofurantoin dosage form.

What excipients are used in nitrofurantoin monohydrate/macrocrystalline capsules?

The Macrobid label identifies a conventional hard-gelatin capsule formulation containing starch, lactose, povidone, magnesium stearate, colloidal silicon dioxide, and capsule-shell materials.[1] Exact inactive-ingredient composition can vary by manufacturer and strength.

A representative excipient architecture is:

Formulation function	Common excipient class	Commercial role
Diluent	Lactose monohydrate	Provides capsule fill mass and supports blend uniformity
Disintegrant	Corn starch	Promotes breakup of the powder plug after administration
Binder	Povidone	Improves granule or powder cohesion
Glidant	Colloidal silicon dioxide	Improves powder flow and filling performance
Lubricant	Magnesium stearate	Reduces tooling and capsule-filling friction
Capsule shell	Gelatin, titanium dioxide, iron oxides or other colorants	Provides dosage-form enclosure, identification, and light protection
Processing aid	Talc or other approved material, depending on manufacturer	Supports flow or manufacturing performance

The product’s performance is driven by more than the nominal excipient list. Critical variables include:

• Nitrofurantoin monohydrate-to-macrocrystal ratio.
• Particle-size distribution and surface area.
• Powder density and flow.
• Blend uniformity at the low-dose-to-excipient ratio.
• Granulation endpoint, if wet or dry granulation is used.
• Lubrication time and magnesium-stearate distribution.
• Capsule fill weight.
• Disintegration and dissolution profiles.
• Food-mediated absorption behavior.

The reference formulation contains 100 mg of drug in a capsule with a relatively high excipient-to-active ratio. That ratio creates opportunities for formulation optimization but also increases the importance of blend segregation and content uniformity controls.

Which excipient strategy is most appropriate for generic nitrofurantoin capsules?

A conservative excipient strategy is the strongest route for a standard ANDA. The formulation should preserve rapid capsule disintegration, comparable dissolution, and the established food-associated exposure profile.

Strategy 1: Use a Q1/Q2-aligned formulation

A Q1/Q2-aligned product uses the same inactive ingredients qualitatively and similar quantities quantitatively to the reference product. This approach can reduce formulation risk and simplify the bioequivalence argument.

Advantages include:

• Lower risk of unexpected dissolution differences.
• Easier interpretation of comparative dissolution data.
• Reduced concern about excipient-mediated absorption changes.
• More predictable capsule-filling behavior.
• Lower risk in post-approval manufacturing transfers.

The disadvantage is limited differentiation. A Q1/Q2-aligned capsule competes primarily on price, supply reliability, and contracting.

Strategy 2: Substitute excipients to reduce cost or supply risk

Potential substitutions include:

• Lactose replacement with microcrystalline cellulose or mannitol.
• Native starch replacement with pregelatinized starch.
• Povidone replacement with copovidone or another compendial binder.
• Colloidal silicon dioxide replacement with an alternative flow aid.
• Gelatin capsule replacement with hypromellose capsules.

Substitution is technically feasible but should be treated as a drug-product development project, not a simple procurement decision. Nitrofurantoin has low aqueous solubility, and changes in wetting, powder deaggregation, and dissolution can alter exposure.

A substitute excipient is commercially attractive only if it produces:

1. Equivalent dissolution across relevant pH conditions.
2. Comparable content uniformity.
3. Stable moisture behavior.
4. Reliable capsule-fill performance.
5. No new impurity or compatibility problem.
6. A bioequivalence profile acceptable to FDA.

Strategy 3: Develop a low-moisture, high-flow capsule blend

A low-moisture strategy can reduce variability during storage and manufacturing. It is particularly relevant where nitrofurantoin particle properties or excipient hygroscopicity produce clumping or fill-weight drift.

Useful development targets include:

• Controlled relative humidity during blending and filling.
• Low water activity.
• Narrow particle-size distribution.
• Optimized silicon-dioxide concentration.
• Short, validated lubrication cycles.
• In-process capsule-weight control.
• Moisture-barrier packaging when supported by stability data.

This strategy can create a manufacturing advantage without changing the clinical product profile.

What formulation patents protect nitrofurantoin monohydrate/macrocrystalline?

The primary commercial product is a mature formulation, and the key historical Macrobid protection was associated with the drug product rather than a new molecular entity. The most relevant protection areas are:

• The mixture of nitrofurantoin monohydrate and macrocrystals.
• Capsule composition.
• Controlled dissolution or release behavior.
• Manufacturing processes for combining the two physical forms.
• Particle-size control.
• Method-of-use claims directed to twice-daily treatment.

For a current generic applicant, the practical question is not whether the original product once had formulation patents. It is whether any listed patent remains enforceable and relevant to the proposed ANDA at filing.

FDA’s Orange Book lists patents and regulatory exclusivity associated with approved drug products. A sponsor should evaluate the current Orange Book listing for the relevant reference product and review any patent certifications required under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2]

Are there active Orange Book patents for Macrobid?

The answer must be determined from the current Orange Book listing at the time of filing. Nitrofurantoin monohydrate/macrocrystalline is a mature product, and the commercial market has long included multiple generic capsule suppliers. That market structure indicates that original product exclusivity has expired or ceased to block ordinary generic entry.

The critical distinction is between:

• Expired patents.
• Delisted patents.
• Unlisted formulation or manufacturing patents.
• Patents that do not cover the proposed ANDA product.
• Patents that could still generate Paragraph IV litigation despite a mature active ingredient.

An applicant should not assume that the absence of a prominent current patent dispute eliminates all legal review. Manufacturing, packaging, device, and method-of-use claims may have different relevance from claims listed in the Orange Book.

When did nitrofurantoin monohydrate/macrocrystalline lose exclusivity?

Nitrofurantoin monohydrate/macrocrystalline is no longer protected by new-chemical-entity exclusivity. Macrobid was approved by FDA in 1995, and the product has been available from multiple generic manufacturers for many years.[1,3]

The commercial exclusivity timeline is:

Milestone	Approximate timing or status
Macrobid NDA approval	1995
NCE exclusivity	Expired long ago
Original formulation patent protection	Expired or no longer a practical barrier to routine generic supply
Generic capsule market	Established
Current commercial risk	Price competition, supply interruptions, manufacturing quality, and substitution economics

FDA approval does not itself create a permanent barrier to generic entry. Generic applicants can rely on the reference product’s safety and efficacy findings through the ANDA pathway, subject to pharmaceutical equivalence, bioequivalence, labeling, manufacturing, and patent-certification requirements.[3]

What are the Paragraph IV risks for nitrofurantoin capsules?

Paragraph IV risk is comparatively limited for an old product with an established generic market, but it is not automatically zero.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic. If the reference-product sponsor or patent owner brings suit within the statutory period after receiving notice, FDA approval can be subject to a 30-month stay, subject to statutory exceptions and litigation developments.[4]

For nitrofurantoin monohydrate/macrocrystalline, the principal legal review areas are:

• Whether the ANDA uses the same active-material combination.
• Whether the proposed product falls within any surviving formulation claim.
• Whether a dissolution or release limitation is claim-relevant.
• Whether the product uses a patented manufacturing sequence.
• Whether a method-of-use patent is carved out of the proposed labeling.
• Whether a patent is listed for the specific reference product rather than another nitrofurantoin dosage form.

The presence of several generic suppliers lowers the probability that a routine capsule applicant will face a major market-blocking patent dispute. It does not eliminate the need for a product-specific freedom-to-operate analysis.

What FDA regulatory requirements affect excipient selection?

FDA’s inactive-ingredient framework is central to formulation strategy. Excipients should be evaluated against the Inactive Ingredient Database, compendial standards, prior oral-capsule precedent, and the proposed maximum daily exposure.[5]

Key regulatory considerations include:

Maximum daily exposure

The recommended Macrobid regimen is 100 mg every 12 hours for seven days, producing a daily nitrofurantoin dose of 200 mg.[1] Excipients must be acceptable at the quantity administered over that treatment period.

Pharmaceutical equivalence

A generic capsule generally must contain the same active ingredient, strength, dosage form, and route of administration as the reference product. Differences in inactive ingredients are permitted when they do not affect safety, efficacy, quality, or bioequivalence.

Bioequivalence

The applicant must demonstrate comparable systemic exposure under FDA’s applicable bioequivalence standards. Food effects are important because the label directs administration with food, and food can affect nitrofurantoin absorption.[1]

Dissolution

Dissolution testing should assess:

• Multiple pH conditions.
• Discriminatory media.
• Fasted and fed-relevant performance where applicable.
• Stability through the proposed shelf life.
• Batch-to-batch reproducibility.
• Sensitivity to particle-size and lubrication changes.

Capsule-shell selection

Hypromellose capsules can reduce reliance on animal-derived gelatin and may support vegetarian or religious-compliance positioning. The substitution can affect moisture transfer, brittleness, shell dissolution, and oxygen exposure. A capsule-shell change requires stability and comparative performance work.

What commercial opportunities exist for nitrofurantoin monohydrate/macrocrystalline?

The product is commercially mature, but several opportunities remain.

1. Low-cost ANDA supply

The most direct opportunity is a reliable generic capsule with:

• Efficient powder handling.
• Low manufacturing loss.
• Dual-source excipients.
• Automated capsule filling.
• High batch yield.
• Simplified packaging.

The market is suitable for manufacturers with scale and strong procurement rather than for high-price specialty positioning.

2. Supply-secure generic manufacturing

Nitrofurantoin has had periodic availability concerns across generic markets. A supplier that maintains redundant API sources, validated alternate excipients, and domestic or regional packaging capacity can win contracts even without the lowest unit price.

Supply differentiation is especially relevant to:

• Hospital purchasing organizations.
• Retail pharmacy chains.
• Government tenders.
• Wholesalers seeking a second source.
• Integrated pharmacy networks.

3. Gelatin-free capsule positioning

A hypromellose capsule can support a differentiated product claim around vegetarian suitability. This is unlikely to support a large premium by itself, but it can improve tender eligibility and portfolio fit.

4. Packaging and adherence programs

Because the usual course is short, commercial value is more likely to come from packaging execution than from complex delivery technology. Potential formats include:

• Seven-day treatment packs.
• Calendar blister packs.
• Unit-dose pharmacy packaging.
• Institutional dispensing packs.
• Tamper-evident or moisture-protective bottles.

Packaging must remain compatible with the reference labeling and applicable state and federal requirements.

5. International licensing and contract manufacture

Markets outside the United States may offer opportunities where:

• Local registration is required.
• A regional manufacturer lacks nitrofurantoin capsule capacity.
• The product is supplied through public-health tenders.
• A licensee can combine local packaging with imported bulk capsules or API.

The key diligence issues are local bioequivalence requirements, pharmacopoeial standards, GMP inspection history, trademark rights, and whether the jurisdiction recognizes the same macrocrystalline formulation.

6. Reformulated delivery systems

A modified-release, pediatric, dispersible, or taste-masked product could create a new commercial position. These approaches carry substantially higher development risk because nitrofurantoin has multiple established dosage forms and a well-defined use case.

The most credible reformulation concepts are:

• Pediatric liquid based on an appropriate nitrofurantoin form.
• Easier-to-swallow capsule technology.
• Unit-dose formulation for adherence.
• Alternative capsule shells.
• Improved moisture protection.

A modified-release formulation would require a strong clinical and pharmacokinetic rationale. The product’s established twice-daily regimen reduces the commercial case for a complex release system.

How strong is the patent estate for nitrofurantoin monohydrate/macrocrystalline?

The patent estate is weak as a barrier to standard generic capsule entry and stronger only for genuinely differentiated products.

IP category	Barrier strength	Commercial assessment
Nitrofurantoin molecule	Low	Long-established active ingredient
Original Macrobid formulation	Low for routine generic entry	Historical protection does not prevent broad generic supply
Monohydrate/macrocrystal ratio	Moderate if narrowly claimed	Relevant to formulation design and infringement review
Particle-size engineering	Moderate	Can support process or formulation claims
Modified-release delivery	Potentially high	New development may support new patent claims
Capsule shell or packaging	Low to moderate	Often useful for differentiation, rarely a broad market barrier
Method of use	Low to moderate	Depends on claim scope and labeling strategy
Manufacturing process	Moderate	May create freedom-to-operate issues if narrowly claimed

A new applicant should focus its IP budget on formulation and process claims that capture measurable performance advantages. Broad claims covering ordinary excipient substitution are likely to face validity and obviousness pressure in a mature product category.

How does nitrofurantoin compare with other urinary antibacterials?

Nitrofurantoin competes mainly with trimethoprim-sulfamethoxazole, fosfomycin, and selected beta-lactams for uncomplicated cystitis. Its commercial positioning is supported by established clinical use and limited systemic exposure, but constrained by renal-function limitations and its indication-specific labeling.[1,6]

Product	Common differentiation	Excipient opportunity
Nitrofurantoin monohydrate/macrocrystalline	Twice-daily capsule with food	Flow control, capsule shell, packaging, supply reliability
Nitrofurantoin macrocrystals	Older nitrofurantoin form	Dose-frequency and tolerability positioning
Fosfomycin tromethamine	Single-dose oral therapy	Sachet, taste, reconstitution, convenience
Trimethoprim-sulfamethoxazole	Broad generic availability	Low-cost tablet and suspension manufacturing
Oral beta-lactams	Alternative treatment class	Pediatric dosage forms and palatability

Nitrofurantoin’s main commercial weakness is that the capsule is a mature generic with limited room for price premiums. Its main strength is a recognizable product platform with established pharmacy demand.

What generic launch risks exist?

Generic launch risks are concentrated in execution rather than basic patent exclusivity.

The principal risks are:

1. Bioequivalence failure caused by particle-size or dissolution differences.
2. Content-uniformity problems from powder segregation.
3. API or excipient supply interruptions.
4. Capsule-fill variability after scale-up.
5. Stability failures related to moisture or shell compatibility.
6. Manufacturing inspection findings.
7. Price erosion after additional ANDA approvals.
8. Product-specific labeling or substitution differences.
9. Inability to secure preferred-wholesaler or pharmacy contracts.
10. Recall exposure from blend, fill-weight, or microbial-control failures.

A commercially viable launch should use a robust control strategy for API particle properties, blend uniformity, dissolution, capsule weight, moisture, and stability.

Key Takeaways

• Nitrofurantoin monohydrate/macrocrystalline is a mature generic opportunity, not an exclusivity-driven product.
• The core formulation uses conventional excipients, including lactose, starch, povidone, colloidal silicon dioxide, magnesium stearate, and hard-capsule shell materials.
• A Q1/Q2-aligned formulation is the lowest-risk route for an ANDA.
• Excipients can be changed, but substitutions must preserve dissolution, food-associated exposure, content uniformity, and stability.
• The strongest commercial advantages are supply reliability, low manufacturing cost, capsule-shell differentiation, and adherence-oriented packaging.
• The Orange Book and current patent records should govern any Paragraph IV or freedom-to-operate decision.
• Modified-release and pediatric products may create new IP, but they carry more regulatory and clinical risk than a standard generic capsule.
• The patent estate is generally weak against routine generic entry and potentially stronger for narrowly claimed particle-size, process, or delivery innovations.

FAQs

Is nitrofurantoin monohydrate/macrocrystalline the same as Macrobid?

Macrobid is the reference brand containing nitrofurantoin monohydrate/macrocrystals in a 100 mg capsule. Generic products must meet applicable FDA requirements for pharmaceutical equivalence and bioequivalence.

Can lactose be removed from nitrofurantoin capsules?

Yes, lactose may be replaced if the alternative formulation satisfies safety, quality, stability, dissolution, and bioequivalence requirements. The substitution should be supported by excipient qualification and comparative product data.

Is nitrofurantoin monohydrate/macrocrystalline suitable for a pediatric product?

The capsule is not the most practical pediatric presentation. A liquid or dispersible product would require separate formulation development, palatability work, dose uniformity controls, stability studies, and regulatory assessment.

Can a manufacturer use a hypromellose capsule instead of gelatin?

Potentially. A hypromellose shell can support vegetarian or animal-origin-free positioning, but the manufacturer must evaluate shell dissolution, moisture transfer, mechanical performance, stability, and comparative bioequivalence.

Does nitrofurantoin have biosimilar competition?

No. Nitrofurantoin is a small-molecule antibacterial, so competition proceeds through generic drug pathways such as ANDAs, not the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Macrobid prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA). FDA.

4. U.S. Food and Drug Administration. (n.d.). Paragraph IV patent certifications and 30-month stays. FDA.

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

6. Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., & Soper, D. E. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 52(5), e103-e120.